ClinicalTrials.gg
RecruitingNCT06630234Updated Nov 12, 2026

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

A Phase 1/2 interventional study of DCC-3009 and Rabeprazole in Gastrointestinal Stromal Tumor (GIST), sponsored by Deciphera Pharmaceuticals, LLC. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Nov 12, 2026Enrollment updatedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
155
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd — 2 open to participants now, 5 under way, 2 of them phase 3. Gastrointestinal Stromal Tumors · Ono Pharmaceutical Co. Ltd.

Started
2024
the only one that year
Phase 1/2
3 of 10
1 open now
Registered
9th of 10
by date

Among the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, this one is the only one that started in 2024, is one of 3 in phase 1/2, and was the 9th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

2 of the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, or all of them as a file.
02

Study summary

The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 3 parts: Part 1 (Dose Escalation), Part 2 (Dose Expansion), and Part 3 (Food Effect [FE] and Drug-Drug Interaction [DDI]). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.

03

Conditions studied

  • Gastrointestinal Stromal Tumor (GIST)

Keywords

  • PDGFRA mutations
  • KIT mutations
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Module A:

  • Have at least 1 as defined by , v1.1
  • Have (ECOG) Performance Status (PS) of 0 or 1
  • Adequate organ function, bone marrow function, and electrolytes
  • All participants agree to comply with the requirements
  • Have a of more than 3 months

Module A Part 1 (Escalation) and Part 3 (FE and DDI):

-Any participant with or cytologically confirmed advanced/unresectable or GIST with documented KIT or -derived growth factor receptor alpha (PDGFRA) mutation, who has progressed on or was intolerant to at least 1 approved tyrosine kinase inhibitor (TKI) regimen in the advanced/metastatic setting

Module A Part 2 (Expansion):

-Any participant with histologically or cytologically confirmed advanced or metastatic GIST with documented KIT or PDGFRA mutation

Module A Part 3 (FE and DDI):

-Able to consume a high-fat meal

Key Exclusion Criteria:

  • Received systemic anticancer therapy or radiotherapy within 14 days prior to first dose of study drug
  • Prior or concurrent that requires treatment or is expected to require treatment for active cancer
  • Has known active central nervous system (CNS) metastases or an active primary CNS cancer
  • History or presence of cardiovascular abnormalities
  • Major surgery within 28 days of the first dose of study drug
  • Had systemic arterial thrombotic or embolic events within 6 months prior to the first dose of study drug
  • Had venous thrombotic events (e.g., deep vein thrombosis) or venous thrombotic embolic events (e.g., pulmonary embolism) within 1 month prior to the first dose of study drug
  • Known allergy or to any component of the study drug
  • Malabsorption syndrome or other illness that could affect oral absorption
  • Any other clinically significant comorbidities

Module A Part 3 (FE and DDI):

  • Allergy or hypersensitivity to rabeprazole or any of its
  • Unable or unwilling to adhere to overnight fasting of 10 hours

Other protocol-specified inclusion and exclusion criteria apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    DCC-3009 Module A

    Participants will receive DCC-3009 in 28 day cycles in Module A Part 1 dose escalation, Part 2 dose expansion, and Part 3 FE and DDI. Participants in Part 3 will also receive rabeprazole.

    Drug: DCC-3009 · Drug: Rabeprazole

Interventions

  • DrugDCC-3009

    Administered orally

  • DrugRabeprazole

    Administered orally (Part 3 only)

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose-Limiting Toxicities (DLT) (Part 1 Escalation)

    DLTs assessed for each dose level.

    Time frame: Cycle 1 (28 Days)

  2. Number of Participants with Treatment-emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) (Part 1 Escalation)

    Time frame: Cycle 1 (28 Days)

  3. Number of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 1 Escalation)

    Time frame: Cycle 1 (28 Days)

  4. Objective Response Rate (ORR) (Part 2 Expansion)

    ORR is the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) based on Modified Response Evaluation Criteria in Solid Tumors (mRECIST), v1.1.

    Time frame: Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)

  5. Pharmacokinetics (PK): Time to Maximum Observed Plasma Concentration (Tmax) (Part 3 FE and DDI)

    Time frame: Estimated up to 24 months

  6. PK: Maximum Observed Plasma Drug Concentration (Cmax) (Part 3 FE and DDI)

    Time frame: Estimated up to 24 months

  7. PK: Trough Plasma Concentration (Ctrough) (Part 3 FE and DDI)

    Time frame: Estimated up to 24 months

  8. PK: Area Under the Plasma Concentration-time Curve (AUC) (Part 3 FE and DDI)

    Time frame: Estimated up to 24 months

Secondary outcomes

  1. Objective Response Rate (ORR) (Part 1 Escalation and Part 3 FE and DDI)

    ORR is the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR) based on mRECIST, v1.1.

    Time frame: Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)

  2. Disease Control Rate (DCR)

    DCR is the proportion of participants who achieve CR, PR, or stable disease at the specified time point per mRECIST, v1.1.

    Time frame: Weeks 16, 24, 32

  3. Duration of Response (DOR)

    DOR for participants with confirmed CR or confirmed PR based on mRECIST, v1.1, defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that the disease progression is objectively documented or death, whichever occurs first.

    Time frame: First Recorded CR or PR until PD or Death (Estimated up to 24 months)

  4. Time to Response (TTR)

    TTR for participants with confirmed CR or confirmed PR based on mRECIST, v1.1, defined as the time from initiation of treatment until the first assessment demonstrating CR or PR per mRECIST, v1.1.

    Time frame: Baseline to First Recorded CR or PR (Estimated up to 24 months)

  5. Progression-Free Survival (PFS)

    PFS is the time from initiation of treatment until documented disease progression per mRECIST, v1.1, or death, whichever occurs first.

    Time frame: Initiation of Treatment to PD or Death (Estimated up to 24 months)

  6. Overall Survival (OS)

    OS is the time from initiation of treatment to the date of death from any cause.

    Time frame: Initiation of Treatment to Death from Any Cause (Estimated up to 24 months)

  7. PK: Tmax (Part 1 Escalation and Part 2 Expansion)

    Time frame: Estimated up to 24 months

  8. PK: Cmax (Part 1 Escalation and Part 2 Expansion)

    Time frame: Estimated up to 24 months

  9. PK: Ctrough (Part 1 Escalation and Part 2 Expansion)

    Time frame: Estimated up to 24 months

  10. PK: AUC (Part 1 Escalation and Part 2 Expansion)

    Time frame: Estimated up to 24 months

  11. Number of Participants with TEAEs or SAEs (Part 2 Expansion and Part 3 FE and DDI)

    Time frame: Estimated up to 24 months

  12. Number of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 2 Expansion and Part 3 FE and DDI)

    Time frame: Estimated up to 24 months

07

Study locations

10 of 10 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for May 2028, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2024
First posted
Oct 8, 2024
StartActual
Dec 10, 2024
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
120→155
Nov 12, 2026
Eligibility
2 criteria edited, 11 added
What changed in the criteria
  • AddedKey Inclusion Criteria:
  • AddedModule A:
  • AddedModule A Part 1 (Escalation) and Part 3 (FE and DDI):
  • Edited-Any participant with histologically or cytologically confirmed advanced/unresectable or metastatic GIST with documented KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation, who has progressed on or was intolerant to at least 1 approved tyrosine kinase inhibitor (TKI) regimen in the advanced/metastatic setting
  • EditedModule A Part 12 (EscalationExpansion):
  • Added-Any participant with histologically or cytologically confirmed advanced or metastatic GIST with documented KIT or PDGFRA mutation
  • AddedModule A Part 3 (FE and DDI):
  • Added-Able to consume a high-fat meal
  • AddedKey Exclusion Criteria:
  • AddedModule A Part 3 (FE and DDI):
  • AddedAllergy or hypersensitivity to rabeprazole or any of its excipients
  • AddedUnable or unwilling to adhere to overnight fasting of 10 hours
  • AddedOther protocol-specified inclusion and exclusion criteria apply.
Nov 12, 2026
Interventions
Added Drug: Rabeprazole
Nov 12, 2026
Primary outcomes
6 added
What changed in the outcomes
  • AddedNumber of Participants with Treatment-emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) (Part 1 Escalation)Time frame: Cycle 1 (28 Days)
  • AddedNumber of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 1 Escalation)Time frame: Cycle 1 (28 Days)
  • AddedPharmacokinetics (PK): Time to Maximum Observed Plasma Concentration (Tmax) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
  • AddedPK: Maximum Observed Plasma Drug Concentration (Cmax) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
  • AddedPK: Trough Plasma Concentration (Ctrough) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
  • AddedPK: Area Under the Plasma Concentration-time Curve (AUC) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
Nov 12, 2026
Secondary outcomes
1 edited, 8 added, 1 removed
What changed in the outcomes
  • EditedObjective Response Rate (ORR) (Part 1 Escalation and Part 3 FE and DDI)Time frame: Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
  • AddedDisease Control Rate (DCR)Time frame: Weeks 16, 24, 32
  • AddedTime to Response (TTR)Time frame: Baseline to First Recorded CR or PR (Estimated up to 24 months)
  • AddedPK: Tmax (Part 1 Escalation and Part 2 Expansion)Time frame: Estimated up to 24 months
  • AddedPK: Cmax (Part 1 Escalation and Part 2 Expansion)Time frame: Estimated up to 24 months
  • AddedPK: Ctrough (Part 1 Escalation and Part 2 Expansion)Time frame: Estimated up to 24 months
  • AddedPK: AUC (Part 1 Escalation and Part 2 Expansion)Time frame: Estimated up to 24 months
  • AddedNumber of Participants with TEAEs or SAEs (Part 2 Expansion and Part 3 FE and DDI)Time frame: Estimated up to 24 months
  • AddedNumber of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 2 Expansion and Part 3 FE and DDI)Time frame: Estimated up to 24 months
  • RemovedPharmacokinetics (PK): Maximum observed plasma drug concentration (Cmax)Time frame: Estimated up to 24 months
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Enrollment 120→155
    Eligibility 2 criteria edited, 11 added
    What changed in the criteria
    • AddedKey Inclusion Criteria:
    • AddedModule A:
    • AddedModule A Part 1 (Escalation) and Part 3 (FE and DDI):
    • Edited-Any participant with histologically or cytologically confirmed advanced/unresectable or metastatic GIST with documented KIT or platelet-derived growth factor receptor alpha (PDGFRA) mutation, who has progressed on or was intolerant to at least 1 approved tyrosine kinase inhibitor (TKI) regimen in the advanced/metastatic setting
    • EditedModule A Part 12 (EscalationExpansion):
    • Added-Any participant with histologically or cytologically confirmed advanced or metastatic GIST with documented KIT or PDGFRA mutation
    • AddedModule A Part 3 (FE and DDI):
    • Added-Able to consume a high-fat meal
    • AddedKey Exclusion Criteria:
    • AddedModule A Part 3 (FE and DDI):
    • AddedAllergy or hypersensitivity to rabeprazole or any of its excipients
    • AddedUnable or unwilling to adhere to overnight fasting of 10 hours
    • AddedOther protocol-specified inclusion and exclusion criteria apply.
    Primary outcomes 6 added
    What changed in the outcomes
    • AddedNumber of Participants with Treatment-emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) (Part 1 Escalation)Time frame: Cycle 1 (28 Days)
    • AddedNumber of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 1 Escalation)Time frame: Cycle 1 (28 Days)
    • AddedPharmacokinetics (PK): Time to Maximum Observed Plasma Concentration (Tmax) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
    • AddedPK: Maximum Observed Plasma Drug Concentration (Cmax) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
    • AddedPK: Trough Plasma Concentration (Ctrough) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
    • AddedPK: Area Under the Plasma Concentration-time Curve (AUC) (Part 3 FE and DDI)Time frame: Estimated up to 24 months
    Secondary outcomes 1 edited, 8 added, 1 removed
    What changed in the outcomes
    • EditedObjective Response Rate (ORR) (Part 1 Escalation and Part 3 FE and DDI)Time frame: Baseline to Progressive Disease (PD), Death due to Any Cause, or Start of New Antitumor Therapy (Estimated up to 24 months)
    • AddedDisease Control Rate (DCR)Time frame: Weeks 16, 24, 32
    • AddedTime to Response (TTR)Time frame: Baseline to First Recorded CR or PR (Estimated up to 24 months)
    • AddedPK: Tmax (Part 1 Escalation and Part 2 Expansion)Time frame: Estimated up to 24 months
    • AddedPK: Cmax (Part 1 Escalation and Part 2 Expansion)Time frame: Estimated up to 24 months
    • AddedPK: Ctrough (Part 1 Escalation and Part 2 Expansion)Time frame: Estimated up to 24 months
    • AddedPK: AUC (Part 1 Escalation and Part 2 Expansion)Time frame: Estimated up to 24 months
    • AddedNumber of Participants with TEAEs or SAEs (Part 2 Expansion and Part 3 FE and DDI)Time frame: Estimated up to 24 months
    • AddedNumber of Participants with Dose Reduction, Interruption, or Discontinuation of Study Drug Due to TEAEs (Part 2 Expansion and Part 3 FE and DDI)Time frame: Estimated up to 24 months
    • RemovedPharmacokinetics (PK): Maximum observed plasma drug concentration (Cmax)Time frame: Estimated up to 24 months
    Interventions Added Drug: Rabeprazole
    + 4 other changes: identifiers, verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06630234
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
Dec 10, 2024
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Team
Contact
clinicaltrials@deciphera.com
888-724-3274
Clinical Team
study director · Deciphera Pharmaceuticals, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion